{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:05:45Z","timestamp":1783688745164,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"French Ministry of Health"},{"name":"Programme Hospitalier de Recherche Clinique","award":["P120118"],"award-info":[{"award-number":["P120118"]}]},{"name":"Programme Hospitalier de Recherche Clinique","award":["NCT02134172"],"award-info":[{"award-number":["NCT02134172"]}]},{"name":"Cerus"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.transci.2019.10.007","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T12:32:11Z","timestamp":1572957131000},"page":"102665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpura"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4102-3714","authenticated-orcid":false,"given":"Olivier","family":"Garraud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Malot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Herbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Ojeda-Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Veyradier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Payrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-9869","authenticated-orcid":false,"given":"Laurence","family":"Corash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2019.10.007_bib0005","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.10.007_bib0010","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.transci.2019.10.007_bib0015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/asheducation-2013.1.292","article-title":"Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies","volume":"2013","author":"Crawley","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.transci.2019.10.007_bib0020","first-page":"15","article-title":"Management of thrombotic thrombocytopenic purpura: current perspectives","volume":"5","author":"Blombery","year":"2014","journal-title":"J Blood Med"},{"key":"10.1016\/j.transci.2019.10.007_bib0025","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1537-2995.2007.01074.x","article-title":"Comparison and stability of ADAMTS13 activity in therapeutic plasma products","volume":"47","author":"Scott","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2019.10.007_bib0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.0958-7578.2004.00478.x","article-title":"Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura","volume":"14","author":"Yarranton","year":"2004","journal-title":"Transfus Med"},{"key":"10.1016\/j.transci.2019.10.007_bib0035","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/asheducation-2015.1.637","article-title":"French Reference Center for Thrombotic Microangiopathies. Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange","volume":"2015","author":"Coppo","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.transci.2019.10.007_bib0040","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","article-title":"Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Page","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.10.007_bib0045","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","article-title":"Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens","volume":"1","author":"Westwood","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2019.10.007_bib0050","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"TITAN investigators. Caplacizumab for acquired thrombotic thrombocytopenic Purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2019.10.007_bib0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"HERCULES investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2019.10.007_bib0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.tracli.2018.07.007","article-title":"Plasma for direct therapeutic use : a short critical overview","volume":"25","author":"Garraud","year":"2018","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.transci.2019.10.007_bib0065","first-page":"149","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-Based approach from the writing committee of the american society for apheresis: the seventh special issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2019.10.007_bib0070","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/vox.12007","article-title":"A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France","volume":"104","author":"Bost","year":"2013","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2019.10.007_bib0075","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/vox.12300","article-title":"Independent evaluation of tolerance of therapeutic plasma inactivated by amotosalen-HCl-UVA (Intercept \u2122) over a 5-year period of extensive delivery","volume":"109","author":"Bost","year":"2015","journal-title":"Vox Sang"},{"issue":"Suppl (1)","key":"10.1016\/j.transci.2019.10.007_bib0080","first-page":"65S","article-title":"Adverse effects of plasma transfusion","volume":"52","author":"Pandey","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2019.10.007_bib0085","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1111\/trf.14245","article-title":"Comparing transfusion reaction rates for various plasma types: a systematic review and meta-analysis\/regression","volume":"57","author":"Saadah","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2019.10.007_bib0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.tracli.2017.10.002","article-title":"Amotosalen-inactivated plasma is as equally well tolerated as quarantine plasma in patients undergoing large volume therapeutic plasma exchange","volume":"25","author":"Guignier","year":"2018","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.transci.2019.10.007_bib0095","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000314710","article-title":"Quarantine plasma: quo vadis?","volume":"37","author":"Roth","year":"2010","journal-title":"Transfus Med Hemother"},{"issue":"June (29)","key":"10.1016\/j.transci.2019.10.007_bib0100","article-title":"Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose","author":"Candotti","year":"2018","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.transci.2019.10.007_bib0105","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.tmrv.2017.05.002","article-title":"Emerging infectious diseases and blood safety: modeling the transfusion-transmission risk","volume":"31","author":"Kiely","year":"2017","journal-title":"Transfus Med Rev"},{"issue":"July (27)","key":"10.1016\/j.transci.2019.10.007_bib0110","article-title":"How to mitigate the risk of inducing transfusion-associated adverse reactions","author":"Garraud","year":"2018","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.transci.2019.10.007_bib0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tracli.2018.07.001","article-title":"Pathogen inactivation\/reduction technologies for platelet transfusion: where do we stand?","volume":"25","author":"Garraud","year":"2018","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.transci.2019.10.007_bib0120","first-page":"277","article-title":"Is solvent\/detergent plasma better than standard fresh-frozen plasma? A systematic review and an expert consensus document","volume":"14","author":"Marietta","year":"2016","journal-title":"Blood Transfus"},{"key":"10.1016\/j.transci.2019.10.007_bib0125","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/vox.12697","article-title":"In vitro quality of amotosalen-UVA pathogen-inactivated mini-pool plasma prepared from whole blood stored overnight","volume":"113","author":"Ravanat","year":"2018","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2019.10.007_bib0130","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.transci.2019.06.004","article-title":"The plasma supply in France","volume":"58","author":"Garraud","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2019.10.007_bib0135","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2019.10.007_bib0140","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.tracli.2017.05.015","article-title":"French reference center for thrombotic microangiopathies. Management of thrombotic thrombocytopenic purpura","volume":"24","author":"Coppo","year":"2017","journal-title":"Transfus Clin Biol"},{"issue":"84","key":"10.1016\/j.transci.2019.10.007_bib0145","article-title":"Blood and blood components: from similarities to differences","volume":"5","author":"Garraud","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.transci.2019.10.007_bib0150","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1423-0410.2011.01562.x","article-title":"Evaluation of the hemostatic potential including thrombin generation of the three different therapeutic pathogen reduced plasmas","volume":"102","author":"Hacquart","year":"2012","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2019.10.007_bib0155","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1537-2995.2007.01488.x","article-title":"Coagulation function in fresh frozen plasla prepared with two photochemical treatment methods: methylene blue and amotosalen","volume":"48","author":"Osselaer","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2019.10.007_bib0160","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombo- cytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangio- pathies Reference Center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.transci.2019.10.007_bib0165","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"French Thrombotic Microangiopathies Reference Centre. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"issue":"September (10)","key":"10.1016\/j.transci.2019.10.007_bib0170","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","author":"Jestin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.10.007_bib0175","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","article-title":"Thrombotic Microangiopathies Reference Center. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"97","author":"Benhamou","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.transci.2019.10.007_bib0180","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/vox.12447","article-title":"The international haemovigilance network database for the surveillance of adverse reactions and events in donors and recipients of blood components: technical issues and results","volume":"111","author":"Politis","year":"2016","journal-title":"Vox Sang"},{"issue":"Suppl (1)","key":"10.1016\/j.transci.2019.10.007_bib0185","first-page":"65S","article-title":"Adverse effects of plasma transfusion","volume":"52","author":"Pandey","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2019.10.007_bib0190","series-title":"Non-inferiority clinical trials to establish effectiveness guidance for industry","author":"FDA","year":"2018"},{"issue":"107","key":"10.1016\/j.transci.2019.10.007_bib0195","article-title":"Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review","volume":"18","author":"Althunian","year":"2017","journal-title":"Trials"},{"issue":"278","key":"10.1016\/j.transci.2019.10.007_bib0200","article-title":"Non-inferiority versus superiority drug claims: the (not so) subtle distinction","volume":"18","author":"Ganju","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.transci.2019.10.007_bib0205","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000323552","article-title":"The use of solvent\/detergent treatment in pathogen reduction of plasma","volume":"38","author":"Hellstern","year":"2011","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.transci.2019.10.007_bib0210","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.transci.2018.02.005","article-title":"Solvent-detergent plasma for the treatment of thrombotic microangiopathies: a canadian tertiary care centre experience","volume":"57","author":"Lee","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2019.10.007_bib0215","doi-asserted-by":"crossref","DOI":"10.1111\/trf.13229","article-title":"Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study","volume":"55","author":"Toussaint-Hacquard","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2019.10.007_bib0220","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/j.1537-2995.2006.00959.x","article-title":"A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura","volume":"46","author":"Mintz","year":"2006","journal-title":"Transfusion"},{"issue":"May (21)","key":"10.1016\/j.transci.2019.10.007_bib0225","article-title":"Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura","author":"Herbrecht","year":"2018","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2019.10.007_bib0230","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1111\/j.1537-2995.2012.03646.x","article-title":"Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011","volume":"52","author":"Som","year":"2012","journal-title":"Transfusion"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050219302290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050219302290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:50:23Z","timestamp":1761468623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050219302290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1473050219302290"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2019.10.007","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2019.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102665"}}